|View printer-friendly version|
|August 02, 2006 1:54 p.m.|
|Teva Announces Global In-Market Second Quarter Sales of Copaxone® Increased 22% to $353 Million|
Jerusalem, Israel, August 2, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of the Sanofi-Aventis group's financial results, that global in-market sales of Copaxone® reached a record $353 million in the second quarter ending June 30, 2006. Once again, Copaxone® was the fastest growing multiple sclerosis (MS) therapy worldwide, with a growth of 22% in sales over the comparable quarter of 2005.